Inhaled insulin Afrezza has launched in India, offering a needle-free option for diabetes management. Designed to overcome ...

Inhaled insulin, a patient-friendly alternative to injections, has been introduced in India. This new method aims to alleviate 'needle phobia' and improve diabetes management.

This form of rapid-acting inhaled insulin, recently introduced in India by the name Afrezza, is said to offer an important ...

H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with an $11 price target after the company’s update. ・The firm said it ...

MannKind closed 2025 on a high note, marked by milestones that reinforce our growth trajectory—including the acquisition of scPharmaceuticals and a record-setting fourth quarter surpassing $100 ...

Type 2 diabetes occurs when the body does not use insulin effectively or does not produce enough insulin to maintain healthy blood sugar levels. Medications aim to lower blood glucose, reduce A1C, and ...

India’s Cipla Limited (BSE: 500087) announced the launch of Afrezza (insulin human) Inhalation Powder in India.

ABSTRACT: Type 2 Diabetes Mellitus (T2DM) is a systemic metabolic disorder with complex pathogenesis. In recent years, a variety of new T2DM drugs have emerged, such as sodium-dependent glucose ...